Zacks Investment Research upgraded shares of Rosetta Genomics (ROSG) from N/A to OUTPERFORM on March 05, 2014, with a target price of $10.50.
Rosetta is a molecular diagnostics company focused on microRNA-based tests for cancers and other indications. The company is currently marketing four cancer assays with focus on its lead cancer origin test. We are optimistic with its microRNA platform technologies, which serve as the basis of continued development of molecular diagnostics. Revenue should get boosted in 2014 and beyond due to focused marketing strategy. Long term pipeline will provide sustainable growth for the years to come. Shares are undervalued at this time. Our price target is $10.50.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Rosetta Genomics (ROSG),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment